

U.S. FDA's PANDA Policy Could Pose Legal Problems for Biosimilars, Attorney Says

October 19, 2021

ATTORNEYS

Landmon, Chad

Brenda Sandburg

Pink Sheet

PRACTICE AREAS

Intellectual Property

Axinn partner Chad Landmon was quoted in the *Pink Sheet* article, "U.S. FDA's PANDA Policy Could Pose Legal Problems for Biosimilars, Attorney Says."

[Click here to access the article.](#) A subscription is required.